Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug
|
| gptkbp:activeDuring |
insulin
|
| gptkbp:administrativeDivision |
injection
once daily |
| gptkbp:clinicalTrials |
gptkb:OPKO_Health
gptkb:United_States Europe 12 months pending Phase 2 |
| gptkbp:collaborations |
various research institutions
|
| gptkbp:competitors |
global diabetes market
|
| gptkbp:contraindication |
severe liver disease
severe kidney disease hypersensitivity to insulin |
| gptkbp:developedBy |
gptkb:OPKO_Health
|
| gptkbp:dosageForm |
solution
|
| gptkbp:drugInterdiction |
beta-blockers
thiazide diuretics other antidiabetic medications |
| gptkbp:formulation |
injectable
|
| gptkbp:futurePlans |
promising
|
| gptkbp:hasCompetitors |
other insulin products
|
| gptkbp:healthcare |
important for efficacy
necessary for safe use |
| https://www.w3.org/2000/01/rdf-schema#label |
OPKO 2900
|
| gptkbp:investmentFocus |
high
|
| gptkbp:is_monitored_by |
weight
blood glucose levels HbA1c levels |
| gptkbp:isResponsibleFor |
under evaluation
|
| gptkbp:market |
high
|
| gptkbp:marketSegment |
under development
|
| gptkbp:partnerships |
with healthcare providers
|
| gptkbp:patentAssignee |
gptkb:OPKO_Health
|
| gptkbp:productionCompany |
clinical trials
|
| gptkbp:purpose |
weight management
long-term management of diabetes |
| gptkbp:regulatoryCompliance |
not approved
FDA_approval_process |
| gptkbp:research |
government grants
private investment |
| gptkbp:researchAreas |
ongoing
|
| gptkbp:researchFocus |
metabolic disorders
|
| gptkbp:route |
subcutaneous
|
| gptkbp:safetyFeatures |
under evaluation
|
| gptkbp:sideEffect |
weight gain
injection site reactions hypoglycemia |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
children
diabetes adults obesity |
| gptkbp:triggerType |
insulin receptor agonist
|
| gptkbp:usedFor |
treatment of various diseases
|